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Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions
of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy
is associated with alterations of PPAR expression in MS patients. We analyzed gene expression of PPAR in peripheral blood
mononuclear cells (PBMC) as well as blood inflammatory markers in women with MS previously medicated with first-line
immunomodulators (baseline) and after NTZ therapy. No differences in PPAR𝛼, PPAR𝛽/𝛿, PPAR𝛾, and CD36 mRNA expression
were found in PBMC between patients under baseline and healthy controls. At three months, NTZ increased PPAR𝛽/𝛿 mRNA
(𝑝 = 0.009) in comparison to baseline, while mRNA expression of PPAR𝛾 and CD36 (a well-known PPAR target gene) was
lower in comparison to healthy controls (𝑝 = 0.026 and 𝑝 = 0.028, resp.). Although these trends of alterations remain after
six months of therapy, the results were not statistically significant. Osteopontin levels were elevated in patients (𝑝 = 0.002) and did
not change during the follow-up period of NTZ treatment. These results suggest that PPAR-mediated processes may contribute to
the mechanisms of action of NTZ therapy.
1. Introduction
Multiple sclerosis (MS) is a demyelinating and neurode-
generative disease of the central nervous system. It is gen-
erally accepted that migration of autoreactive T cells and
monocytes across the blood-brain barrier (BBB) is of critical
importance for the pathogenesis of the disease. Peroxisome
Proliferator-Activated Receptors (PPAR) are transcription
factors involved in metabolic and immune processes [1]
and regulate T cell-mediated autoimmunity and severity
of experimental autoimmune encephalomyelitis (EAE), an
animal model of multiple sclerosis (MS) [2–4]. In MS
patients, peripheral bloodmononuclear cells (PBMC) exhibit
decreased PPAR𝛾 expression inversely correlated with dis-
ease activity and PPAR𝛾 agonists may have beneficial effects
[4–6]. Some studies have suggested that PPAR𝛼 [2] and
PPAR𝛽/𝛿 [7] specific agonists should also be considered as
possible therapeutic strategies for this disorder.
In the present exploratory study we analyzed patients
treated with Natalizumab (NTZ), a humanized monoclonal
antibody against 𝛼4 integrin molecules that inhibits transmi-
gration of leukocytes to the CNS and induces complex alter-
ations of immune functions in peripheral circulation [8–10].
However, the mechanisms underlying the beneficial effects
and potential adverse events of this treatment in MS are not
fully understood. Based on the literature, we hypothesized
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that NTZ therapy could change PPAR and CD36 gene
expression in PBMC. CD36 is an innate immune receptor
expressed in endothelial cells and microglia/macrophages
upregulated by PPAR𝛾 [1]. Blood levels of metalloproteinase-
9 (MMP-9), neopterin, and osteopontin (OPN) were also
measured, since their expression may be modulated by PPAR
[1] and MS therapies [8, 11, 12].
2. Material and Methods
2.1. Patients. Twelve female patients, with relapsing-
remitting MS (RRMS) and scheduled to start treatment with
NTZ, were recruited from two MS clinical centers in Lisbon
(Portugal). The mean age of these patients was 43 years (SD:
12); the mean duration of the disease 11.6 years (SD: 8.8);
the mean expanded disability status scale is 4.1 (SD: 1.9);
and the annualized relapse rate is 2.9 (SD: 1.7). The mean
annualized relapse rate was calculated on the basis of the
number of relapses occurring in each subject the previous
two years under first-line immunomodulator treatment.
Eleven patients received interferon beta-1a (Rebif, 44 𝜇g s.c.)
3 times weekly or interferon-1b (Betaferon, 250𝜇g s.c.) every
other day. One patient was medicated with glatiramer acetate
injections. Blood samples were collected from these patients
after a one-week washout period before starting treatment
with 300mg NTZ intravenously once monthly (baseline).
At sampling, no patient was suffering from a relapse nor
taking lipid-lowering agents and none had been treated
with steroids for at least 1 month. Blood samples were also
obtained at three and six months after switching therapy,
just before the infusion of NTZ. During this study period,
no patient suffered from a relapse or was medicated with
corticosteroids. All patients and nine age-matched female
healthy controls signed an informed consent. The local
Ethics Committee approved this study.
2.2. RNA Extraction and PCR Analysis. Blood was processed
immediately after venipuncture and PBMC were collected
by a lymphocyte separation medium gradient. Purifica-
tion of mRNA was processed using QIAamp RNA Blood
Mini Kit (Qiagen), according to the manufacturer’ protocol.
PPAR𝛼, PPAR𝛽/𝛿, PPAR𝛾, and CD36 mRNA expression
in PBMC was evaluated by quantitative RT-PCR. RNA
was reverse-transcribed using random hexamer primers and
Superscript reverse transcriptase (Life Technologies, France)
and cDNAs were quantified either by Brilliant III Ultra-
Fast SYBRGreen using specific oligonucleotides (for PPAR𝛾,
CD36 and cyclophilin) or by Kit Brilliant Multiplex QPCR
MasterMixAgilent to simultaneously detect the expression of
PPAR𝛼, PPAR𝛽/𝛿, and cyclophilin on an Mx3000 apparatus
(Stratagene, La Jolla, CA) (see Supplementary Information
available online at http://dx.doi.org/10.1155/2016/5716415 for
primers and probes used). The relative expression of each
gene was calculated by the ΔCt method, where ΔCt is the
value obtained by subtracting the Ct (threshold cycle) value
of cyclophilin mRNA from the Ct value of the target gene.
The amount of target relative to the cyclophilin mRNA was
expressed as 2−(ΔCt).
2.3. Biochemistry Assays. Plasma and serum were collected
from the same samples and stored at −80∘C until use. Com-
mercially available enzyme-linked immunosorbent assays
(ELISA)were used formeasurement ofMMP-9, OPN (Quan-
tikine ELISAKits, R&DSystems Europe, Abingdon,UK), and
neopterin (ELISA Kit, IBL, Hamburg, Germany).
2.4. Statistical Analysis. Expression of PPAR𝛼, PPAR𝛽/𝛿,
PPAR𝛾, and CD36 mRNA and inflammatory marker con-
centrations were compared between patients and healthy
controls using two-sample 𝑡-tests. The change from baseline
in these parameters at three and six months on NTZ therapy
was analyzed using one-sample 𝑡-tests. The correlations
between the changes in PPAR expression and the changes
in inflammatory mediators were carried out using Pearson’s
correlation coefficient. A 𝑝 value < 0.05 was considered
statistically significant.
3. Results
The results concerning PPAR and CD36mRNA in the PBMC
of the studied population are presented in Figure 1. No
differences in PPAR𝛼, PPAR𝛽/𝛿, PPAR𝛾, and CD36 mRNA
expression between patients under baseline treatment and
healthy controls were found. At three months on NTZ,
patients had higher PPAR𝛽/𝛿 mRNA expression in compar-
ison to baseline (mean difference 14.5 (95% CI: 4.4, 24.6),
𝑝 = 0.009). In addition, NTZ treated patients had lower
PPAR𝛾 (difference in means −64 (95% CI: −120, −9), 𝑝 =
0.026) and CD36 (difference in means −32 (95% CI: −60,
−4), 𝑝 = 0.028) mRNA expression at three months than
normal controls. CD36 level was also lower in comparison
to baseline (mean difference −32 (95% CI: −60, −4), 𝑝 =
0.028). Although this trend of alterations remained after six
months on NTZ therapy the results were not statistically
significant. In contrast, this treatment did not change PPAR𝛼
gene expression in PBMC.
Plasma concentrations of inflammatory markers are pre-
sented in Table 1. No statistically significant differences in
MMP-9 protein levels between patients and healthy controls
were found. Patients under baseline had higher neopterin
levels than healthy controls (difference in means 3.9 (95% CI:
0.4, 7.3), 𝑝 = 0.029). NTZ therapy decreased neopterin to
normal levels. Patients had higher OPN levels than healthy
controls under baseline (difference in means 53 (95% CI:
23, 84), 𝑝 = 0.002) and at three months (difference in
means 30 (95% CI: 10, 50), 𝑝 = 0.006) and six months
(difference in means 33 (95% CI: 10, 56), 𝑝 = 0.007)
on NTZ therapy. No statistically significant correlations
between the changes in PPAR expression and the changes
of inflammatory mediators were observed (data not shown).
These results remain unchanged whether the patient who
received glatiramer acetate treatment was excluded from the
analysis.
4. Discussion
This exploratory study suggests that NTZ induces selective
alterations of PPAR𝛽/𝛿 and PPAR𝛾 gene expression in
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Figure 1: Expression of PPAR𝛼, PPAR𝛽/𝛿, PPAR𝛾, and CD36 in PBMC of healthy controls and patients. PBMC were isolated from healthy
controls and patients at baseline and after 3 (T3) or 6 months (T6) of treatment with NTZ. mRNA levels of PPAR𝛼 (a), PPAR𝛽/𝛿 (b), PPAR𝛾
(c), andCD36 (d) weremeasured byQ-PCR.The relative expression of each genewas calculated as described above, normalized to cyclophilin
mRNA, and expressed as means ± SD relative to healthy controls set at 100.
Table 1: Inflammatory markers.
Markers Healthy controls
MS patients
Baseline treatment Natalizumab
𝑝 3 months 𝑝∗ 𝑝∗∗ 6 months 𝑝∗∗∗
MMP-9 636.3 (349.9) 565.7 (280.7) 0.613 474.7 (214.1) 0.205 0.446 467.2 (209.2) 0.385
Neopterin 5.7 (1.4) 9.6 (4.8) 0.029 6.6 (1.4) 0.144 0.033 6.0 (0.5) 0.018
Osteopontin 51.1 (18) 104.1 (40.6) 0.002 81 (24.5) 0.006 0.073 84.2 (29.1) 0.225
Values shown are mean (± SD) ng/mL.
𝑝—comparison between patients at baseline and healthy controls.
𝑝∗—comparison between patients at three months on Natalizumab therapy and healthy controls.
𝑝∗∗—comparison between patients at baseline and at three months on Natalizumab therapy.
𝑝∗∗∗—comparison between patients at baseline and at six months of Natalizumab therapy.
PBMC of women with MS. This treatment is associated with
peripheral sequestration of activated T cells and increased
production of proinflammatory cytokines in the blood [8–
10]. Inflammatory stimulation decreases PPAR𝛾 promoter
activity and gene transcription and PPAR𝛾 agonists are anti-
inflammatory and able to upregulate CD36 expression [1,
4, 5]. Therefore, the induction of systemic inflammation by
NTZ could explain a decrease of PPAR𝛾 and CD36 gene
expression in the PBMC of patients. Importantly, systemic
inflammatory activity has been linked to the beneficial effects
of NTZ in reducing biomarkers of intrathecal inflammation
[8, 9]. It is well accepted that NTZ blocks 𝛼4𝛽1 (VLA-
4) integrin-mediated leukocyte transmigration to the CNS
[8–10]. In this regard, it is interesting that PPAR𝛾 may
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regulate the expression of 𝛽1 integrin [13]. Moreover, in MS
patients free of therapy, a pronounced elevation of PPAR𝛾
levels in the cerebrospinal fluid (CSF) was associated with
increased intrathecal inflammation [14]. Overall, these data
suggest that PPAR𝛾-mediated processes may contribute to
the mechanism of action of NTZ. In contrast, PPAR𝛽/𝛿
gene expression increased by this drug. PPAR𝛽/𝛿 has a
complex role in immune regulation. Although PPAR𝛽/𝛿
agonists have strong anti-inflammatory effects, they may
also induce some immune stimulatory components [15]. In
experimental models, PPAR𝛽/𝛿 expression mediates distinc-
tive mechanisms in suppressing CNS autoimmunity [3] and
promoting myelination [7]. Therefore, the present results
could indicate a link between PPAR𝛽/𝛿 upregulation and the
protective effects of NTZ. It is remarkable that PPAR𝛼mRNA
levels were unchanged in our cohort of MS women. In fact,
PPAR𝛼 expression was shown to modulate the production of
proinflammatory cytokines and the development of EAE in
males but not in females [2]. These findings suggest that it
would be important to analyzewhether PPAR𝛼 alsomodulate
gender-related differences in the mechanisms of action of
NTZ therapy.
It was not unexpected that plasma neopterin levels
increased at baseline, since most patients have been medi-
cated with interferon beta. The mechanism of action of this
treatment is known to increase this inflammatory marker of
macrophage activation [11]. Notably, early in the course of
NTZ therapy, plasma neopterin decreased to normal levels.
As reported in most studies, plasma OPN was increased in
our patients previously medicated with immunomodulators
[12, 16]. Nevertheless, in contrast to neopterin, OPN levels
were not significantly changed during the first six months
on NTZ therapy. In a recent study, NTZ decreased OPN
levels only after 12 months of treatment in correlation with
an improvement of cognitive functions [12]. In this regard,
it is of potential relevance that PPAR𝛾 and PPAR𝛼 agonists
have inhibitory effects on OPN gene expression [17, 18]. The
systemic profile of T cells activation and cytokine production
induced by NTZ treatment has been shown to be time-
dependent and may change differently in single subjects [9,
10]. A major limitation of the present results concerns the
small size of the studied population and the short follow-up
period of treatment. Therefore, they do not exclude a role of
PPAR in modulating patients’ response to this therapy. This
should be tested in a larger sample cohort under a longer
period of treatment and including other cytokine measure-
ments and imaging data. A major concern associated with
the continuation of NTZ therapy regards the increased risk
for latent virus-infection activation, including the occurrence
of progressivemultifocal leukoencephalopathy. In the present
context, it is to note that plasma OPN is especially increased
in HIV-infected patient displaying cognitive complains [19]
and that PPAR𝛾 and PPAR𝛼 agonists may protect against
HIV-induced inflammatory responses [20].
In conclusion, our findings suggest that NTZ therapy
induces selective alterations of PPAR-mediated processes in
circulating immune cells. These results need to be confirmed
in a larger cohort of patients and longer follow-up periods of
treatment. Along the reviewed data, they suggest that PPAR
should be considered as potential useful biomarkers of MS
patient response to NTZ therapy.
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